Overseas approval and sales
would have been a good idea 2 or 3 years ago when IMGG had money and time. Not now as a desperation move where you need approval and sales quickly.
There just isn't this magical country out there that has little to no regulation and a bounty of healthcare technology dollars to buy junk that can't manage approval in other countries.
But you might want to ask yourself, why the extreme reluctance to provide the imaging study that the FDA is requiring???
All along, Dean has been saying it's a matter of clearing up some minor details. Then a full year elapses before he even bothers going to the FDA to discuss the rejection (meeting was held less than 30 days from the time he requested it).
Then 4 months after the meeting, he's not looking for alternate routes while he waits for approval? Lightbulb shoud go off that there is no "summer submission". He's looking at anywhere from a year to never if he's looking at parallel tracks.
And where does the money come from for this parallel track? Last I checked IMGG was broke, had leftover lenders getting shares at 5 cents, and a million dollars worth of floorless convertible debentures on the books (price gets adjusted downward an unlimited amout of times)
Me thinks IMGG's lenders want some assurance there will be PR material when they start converting shares
Dean's previewing his material for you.
Why doesn't he just tell the truth about what the delay in acquiring images is all about. Release his FDA correspondence.
News 
Market Data 
Discover 
